Open AccessPost-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus
Author(s) -
Hiroshi Yoshitani,
Junko Itô,
Hideki Kozono
Publication year - 2022
Publication title -
hepatic medicine
Language(s) - English
Resource type - Journals
ISSN - 1179-1535
DOI - 10.2147/hmer.s352775
Subject(s) - medicine , visual analogue scale , incidence (geometry) , adverse effect , disease , postmarketing surveillance , drug withdrawal , drug , drug reaction , surgery , pharmacology , physics , optics
Nalfurafine (Remitch ® , Toray Industries, Inc.) is a selective κ-receptor agonist approved in Japan for the improvement of pruritus in patients with chronic liver diseases (only when existing treatments bring insufficient efficacy) in May 2015.